Bayer chief executive Bill Anderson has said that newer product launches have offset the decline in sales of anticoagulant ...

Bayer's big investment in time and money on the development of finerenone for chronic kidney disease (CKD) in diabetics has paid off with an FDA approval, although it could face stiff competition ...

selective mineralocorticoid receptor antagonist finerenone (Kerendia, Bayer), finerenone reduced risk for death, HF hospitalization and a composite of kidney-related endpoints compared with placebo.

Bayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for Kerendia (finerenone) to treat a new indication.The sNDA seeks ...

the cardiovascular and kidney benefits of Bayer’s Kerendia (finerenone) are maintained regardless of acute changes in estimated glomerular filtration rate (eGFR) following treatment initiation ...

A recent analysis compared the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and finerenone (Kerendia; Bayer).